Author: Crawford, K. H.; Dingens, A. S.; Eguia, R.; Wolf, C. R.; Wilcox, N.; Logue, J. K.; Shuey, K.; Casto, A. M.; Fiala, B.; Wrenn, S.; Pettie, D.; King, N. P.; Chu, H. Y.; Bloom, J. D.
Title: Dynamics of neutralizing antibody titers in the months after SARS-CoV-2 infection Cord-id: 6152i9os Document date: 2020_8_7
ID: 6152i9os
Snippet: Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between {approx}30 and 152 days post-symptom onset from a prospective cohort of 34 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four mo
Document: Most individuals infected with SARS-CoV-2 develop neutralizing antibodies that target the viral spike protein. Here we quantify how levels of these antibodies change in the months following SARS-CoV-2 infection by examining longitudinal samples collected between {approx}30 and 152 days post-symptom onset from a prospective cohort of 34 recovered individuals with asymptomatic, mild, or moderate-severe disease. Neutralizing antibody titers declined an average of about four-fold from one to four months post-symptom onset. Importantly, our data are consistent with the expected early immune response to viral infection, where an initial peak in antibody levels is followed by a decline to a lower plateau. Additional studies of long-lived B-cells and antibody titers over longer time frames are necessary to determine the durability of immunity to SARS-CoV-2.
Search related documents:
Co phrase search for related documents- acute infection and longitudinal cohort study: 1, 2, 3, 4, 5, 6, 7, 8
- acute infection and luciferase activity: 1
- acute infection and luciferase assay system: 1
Co phrase search for related documents, hyperlinks ordered by date